Ciclo celular / Checkpoint
Los inhibidores del ciclo celular/puntos de control son compuestos que interrumpen la progresión normal del ciclo celular, particularmente en puntos de control regulatorios clave. Estos inhibidores son cruciales para estudiar la división celular, comprender la proliferación de células cancerosas y desarrollar terapias anticancerígenas. Al dirigirse a fases específicas del ciclo celular, estos inhibidores pueden inducir la detención del ciclo celular, lo que lleva a apoptosis o senescencia en células de división rápida. En CymitQuimica, ofrecemos una amplia gama de inhibidores de alta calidad del ciclo celular/puntos de control para apoyar su investigación en biología del cáncer, biología celular y desarrollo de fármacos.
Subcategorías de "Ciclo celular / Checkpoint"
- Aurora quinasa(94 productos)
- CDK(500 productos)
- Detención del ciclo celular(4 productos)
- Chk(42 productos)
- DYRK(48 productos)
- Dynamin(23 productos)
- Ferroptosis(215 productos)
- HSP(169 productos)
- Integrin(224 productos)
- Kinesina(66 productos)
- LIM quinasa(19 productos)
- Asociado a microtúbulos(261 productos)
- PKC(102 productos)
- PLK(28 productos)
- ROCK(70 productos)
- Rho(2 productos)
- Wee1(15 productos)
- c-Myc(69 productos)
Mostrar 10 subcategorías más
Se han encontrado 3477 productos de "Ciclo celular / Checkpoint"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Forma y color:SolidPeso molecular:359.355PolQi1
CAS:<p>PolQi1 is a highly efficient and selective Polϴ (DNA polymerase theta) inhibitor with an IC50 of 2 nM, showing potential for cancer therapy.</p>Fórmula:C18H14ClF5N4O2Pureza:98.97%Forma y color:SolidPeso molecular:448.77NusB-IN-1
<p>NusB-IN-1 (22r) is an oral bacterial rRNA inhibitor, effective against MRSA and VRSA.</p>Fórmula:C21H16N2O3Forma y color:SolidPeso molecular:344.36ROCK-IN-11
CAS:<p>ROCK-IN-11 (example 94) is an effective inhibitor of ROCK1 and ROCK2, with an IC50 of ≤ 5 μM, and plays a significant role in cancer research.</p>Fórmula:C22H20N4O4SForma y color:SolidPeso molecular:436.484WEE1-IN-11
CAS:<p>WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.</p>Fórmula:C26H29FN8OS2Forma y color:SolidPeso molecular:552.69PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Forma y color:SolidPeso molecular:425.53WEE1 degrader 1
<p>WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.</p>Fórmula:C30H31N5O3Forma y color:SolidPeso molecular:509.6CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SForma y color:SolidPeso molecular:437.52Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SForma y color:SolidPeso molecular:272.28Uridine 3',5'-diphosphate
CAS:<p>Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) serves as a competitive RNase inhibitor [1].</p>Fórmula:C9H14N2O12P2Forma y color:SolidPeso molecular:404.16Dyrk1A-IN-4
CAS:<p>Dyrk1A-IN-4, compound 48, is an oral DYRK1A/DYRK2 inhibitor with IC50s: 2 nM (DYRK1A), 6 nM (DYRK2), anticancer properties.</p>Fórmula:C14H13F3N6Forma y color:SolidPeso molecular:322.29DHX9-IN-9
CAS:<p>DHX9-IN-9 (509) acts as an inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.0177 μM in DHX9 cellular target engagement, primarily utilized in cancer research [1].</p>Fórmula:C21H21ClFN5O3S2Forma y color:SolidPeso molecular:510Plevitrexed
CAS:<p>Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.</p>Fórmula:C26H25FN8O4Pureza:98%Forma y color:SolidPeso molecular:532.532′-O-MOE-CMP
CAS:<p>2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.</p>Fórmula:C12H20N3O9PForma y color:SolidPeso molecular:381.28RAD51-IN-8
<p>RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.</p>Fórmula:C16H14Cl2FN3O2Forma y color:SolidPeso molecular:370.21CIB-L43
CAS:<p>CIB-L43 is a oral TRBP inhibitor, inhibit miR-21, increase PTEN and Smad7, and block the AKT and TGF-β，inhibit proliferation and migration.</p>Fórmula:C15H16N2O3SPureza:99.64%Forma y color:SolidPeso molecular:304.36Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47Polθ-IN-8
CAS:<p>Polθ-IN-8 (example 77) is a DNA polymerase θ (Polθ) inhibitor with an IC50 for Polθ ATPase activity of less than 100 nM. Polθ-IN-8 is useful for researching diseases related to Polθ activity, such as cancer.</p>Fórmula:C22H22ClN7O3SForma y color:SolidPeso molecular:499.97Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Forma y color:SolidPeso molecular:303.31
